France· FR:69293541
VANFLYTA 17,7 mg, comprimé pelliculé
A medicinal product containing dichlorhydrate de quizartinib, registered in France by DAIICHI SANKYO EUROPE (ALLEMAGNE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DICHLORHYDRATE DE QUIZARTINIB
- Manufacturer
- DAIICHI SANKYO EUROPE (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip13340093028263228 plaquettes aluminium de 1 compriméEUR 5.42
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dichlorhydrate de quizartinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVANFLYTADaiichi Sankyo Europe GmbH, Mnichov
- SwitzerlandVANFLYTA 17.7 mg, FilmtablettenDaiichi Sankyo (Schweiz) AG
- FinlandVANFLYTADaiichi Sankyo Europe GmbH
- IrelandVANFLYTA 17.7 mg film-coated tabletsDaiichi Sankyo Europe GmbH
- IcelandVANFLYTADaiichi Sankyo Europe GmbH
- NetherlandsVANFLYTA 17,7 mg filmomhulde tablettenDAIICHI SANKYO EUROPE GmbH
- NorwayVanflytaDaiichi Sankyo Europe GmbH
- PolandVanflytaDaiichi Sankyo Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vanflyta
- Liechtenstein · Vanflyta
- Norway · Vanflyta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b87d2a7c-d508-404d-be0b-47ef37b2ce75 GET /v1/drugs/b87d2a7c-d508-404d-be0b-47ef37b2ce75?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69293541",
"date_amm": "2023-11-06",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1768",
"substance": "DICHLORHYDRATE DE QUIZARTINIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about dichlorhydrate de quizartinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.